Axsome Therapeutics (AXSM) Misses Q3 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts AXSM Hot Sheet
Join SI Premium – FREE
Axsome Therapeutics (NASDAQ: AXSM) reported Q3 EPS of ($0.95), $0.10 worse than the analyst estimate of ($0.85). Revenue for the quarter came in at $171 million versus the consensus estimate of $162.45 million.
For earnings history and earnings-related data on Axsome Therapeutics (AXSM) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JELD-WEN Holding, Inc. (JELD) Tops Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- The Mosaic Company (MOS) Misses Q3 EPS by 20c, Beats on Revenue
- Horace Mann Educators (HMN) Tops Q3 EPS by 98c; offers guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
